OPEN

Glomerular function in relation to fine airborne particulate matter in a representative population sample

Ying-Mei Feng^{1,2}✉, Lutgarde Thijs², Zhen-Yu Zhang², Esmée M. Bijnen³, Wen-Yi Yang^{2,4}, Fang-Fei Wei^{2,5,6}, Bram G. Janssen³, Tim S. Nawrot³ & Jan A. Staessen^{7,8}✉

From 1990 until 2017, global air-pollution related mortality increased by 40%. Few studies addressed the renal responses to ultrafine particulate [$\leq 2.5 \mu\text{m}$ (PM_{2.5})], including black carbon (BC), which penetrate into the blood stream. In a Flemish population study, glomerular filtration estimated from serum creatinine (eGFR) and the urinary albumin-to-creatinine ratio were measured in 2005–2009 in 820 participants (women, 50.7%; age, 51.1 years) with follow-up of 523 after 4.7 years (median). Serum creatinine, eGFR, chronic kidney disease (eGFR $< 60 \text{ mL/min/1.73 m}^2$) and microalbuminuria ($> 3.5/2.5 \text{ mg per mmol creatinine in women/men}$) were correlated in individual participants via their residential address with PM_{2.5} [median 13.1 (range 0.3–2.9) $\mu\text{g/m}^3$] and BC [1.1 (0.3–18) $\mu\text{g/m}^3$], using mixed models accounting for address clusters. Cross-sectional and longitudinally, no renal outcome was associated with PM_{2.5} or BC in models adjusted for sex and baseline or time varying covariables, including age, blood pressure, heart rate, body mass index, plasma glucose, the total-to-HDL serum cholesterol ratio, alcohol intake, smoking, physical activity, socioeconomic class, and antihypertensive treatment. The subject-level geocorrelations of eGFR change with to BC and PM_{2.5} were 0.13 and 0.02, respectively ($P \geq 0.68$). In conclusion, in a population with moderate exposure, renal function was unrelated to ultrafine particulate.

Abbreviations

BC	Black carbon
FLEMENGHO	Flemish Study on Environment, Genes and Health Outcomes
CKD-EPI	Chronic Kidney Disease Epidemiology Collaboration
CKD	Chronic kidney disease
eGFR	Estimated glomerular filtration rate derived from serum creatinine

According to the report of the Global Burden of Disease Study, renal failure contributed to 0.403 million death in 1990 which increased to 0.736 million in 2010 worldwide¹. The subsequent 2017 report confirmed this trend and highlighted the contribution of environmental pollutants, including air pollution, as driver of chronic kidney disease (CKD)². From 1990 until 2017, global mortality and disability adjusted life-years (DALYs) related to ambient air pollution by particulate matter increased by 39.35% and 43.45%, respectively².

Airborne fine particulate (PM_{2.5}) reaches the smallest airways and alveoli, crosses the blood-air barrier and directly penetrates into the blood stream³. Black carbon (BC), a component of PM_{2.5}, consists of pure carbon in several bond forms, and finds its origin in the incomplete combustion of fossil fuels, biofuel or biomass. The kidneys clear BC particles from the circulating blood⁴. The number of carbon particles in urine is measurable and

¹Department of Science and Technology, Beijing Youan Hospital, Capital Medical University, Beijing 100069, China. ²Research Unit Hypertension and Cardiovascular Epidemiology, KU Leuven Department of Cardiovascular Sciences, University of Leuven, Leuven, Belgium. ³Center for Environment Sciences, Hasselt University, Diepenbeek, Belgium. ⁴Shanghai General Hospital, Shanghai, China. ⁵Department of Cardiology, The First Affiliated Hospital of Sun Yat-Sen University, Guangzhou, Guangdong, China. ⁶NHC Key Laboratory of Assisted Circulation, Sun Yat-Sen University, Guangzhou, China. ⁷Non-Profit Research Institute Alliance for the Promotion of Preventive Medicine, Mechlin, Belgium. ⁸Biomedical Sciences Group, Faculty of Medicine, University of Leuven, Leuven, Belgium. ✉email: yingmeif13@sina.com; jan.staessen@appremed.org

reflects chronic exposure to combustion-related air pollution⁴. Several studies reported on the levels of particulate matters in relation to the glomerular filtration rate estimated from serum creatinine (eGFR)^{5–8}, glomerulopathy⁹, prevalent⁷ or incident¹⁰ CKD, progression to end-stage renal disease¹⁰, microalbuminuria¹¹, and the risk of renal cancer¹² in relation to air pollutants. These studies enrolled population samples^{11,12}, stroke patients⁵, or aged male veterans^{6,8,10}. Some studies did not report the level of exposure¹¹, or estimated exposure from the proximity of major roads⁵, while other findings were representative for exposure levels far above current air quality standards. Other reports focused on coarse particulate⁷. Of the eight reviewed studies^{5–9,11,12}, none reported on BC exposure. To address this knowledge gap, we analysed data from The Flemish Study on Environment, Genes and Health Outcomes (FLEMENGHO), a family-based population study with catchment area in northern Belgium.

Results

Baseline characteristics of participants. All 820 participants were White Europeans, of whom 416 (50.7%) were women. Age at baseline (2005–2009) averaged (SD) 51.1 (15.6) years (5th–95th percentile interval, 23.6–75.8 years). Among 820 participants, 341 (41.6%) had hypertension, of whom 211 (61.9%) were on antihypertensive drug treatment, 75 (5.1%) had a history of cardiovascular disease, and 32 (3.9%) had diabetes. Among 211 patients on antihypertensive drug treatment, 18 (8.5%) took diuretics, 94 (44.6%) inhibitors of the renin system, 17 (8.1%) vasodilators, 2 (0.9%) centrally acting α_2 adrenergic agonists and 80 (37.9%) were on combination therapy with more than one class of blood pressure lowering medication. Intake of statins was reported by 106 participants (12.9%). Serum creatinine and eGFR averaged 86.4 (15.5) $\mu\text{mol/L}$ and 80.9 (16.4) mL/min/1.73m^2 , respectively and were approximately normally distributed (Supplementary Figure S1). The association between serum creatinine and age was curvilinear (Supplementary Figure S2). At baseline, 264 people (32.2%) were in CKD stage 1, 487 in CKD stage 2 (59.4%), 55 in CKD stage 3A (6.7%), 12 in CKD stage 3B (1.5%), 2 in CKD stage 4 (0.2%) and none in CKD stage 5. At baseline, the prevalence of microalbuminuria based on the urinary albumin-to-creatinine ratio was 14 (3.4%) in women and 15 (3.7%) in men.

Tables 1 and 2 list the characteristics of the participants by thirds of the distributions of BC and $\text{PM}_{2.5}$, respectively. Most clinical and biochemical characteristics were similar across thirds of the BC and $\text{PM}_{2.5}$ distributions, with the exception of plasma glucose which decreased from the lowest to the highest exposure group for both BC ($P=0.027$) and $\text{PM}_{2.5}$ ($P=0.033$), and the prevalence of smoking ($P=0.027$) which was higher in the top $\text{PM}_{2.5}$ exposure group.

Ambient air pollution. The median interval between the assessment of renal function and the midpoint assessment of long-term air pollution (30 June 2012) was 5.6 years (5th–95th percentile interval, 3.1–6.9 years) at baseline (2005–2009) and 0.4 years (0.6–2.6 years) at follow-up (2009–2013). Of the 820 participants, 231 lived alone, while 165, 33 and 38 shared a home with two, three or more participants. The median long-term air pollution levels (5th–95th percentile interval), to which participants were exposed, amounted to 1.10 $\mu\text{g/m}^3$ (0.93–1.55 $\mu\text{g/m}^3$) for BC and 13.1 $\mu\text{g/m}^3$ (12.4–15.3 $\mu\text{g/m}^3$) for $\text{PM}_{2.5}$. While accounting for clustering among study participants sharing a residential address, the levels of the two air pollutants were highly correlated ($r=0.95$).

Cross-sectional analyses. In multivariable-adjusted cross-sectional analyses of all participants, serum creatinine, eGFR and the prevalence of CKD and microalbuminuria were unrelated to BC and $\text{PM}_{2.5}$, irrespective of whether only the baseline data were used, only the follow-up data, or the baseline and follow-up data (Table 3, $P\geq 0.49$). All models accounted for clustering of data among participants living at the same address and were adjusted for sex, age (linear and squared term), mean arterial pressure, heart rate, body mass index, plasma glucose, total-to-HDL cholesterol ratio, γ -glutamyltransferase as biomarker of alcohol consumption, smoking, daily energy expenditure in physical activity, socioeconomic class, and antihypertensive treatment (by drug class). A correlation matrix between continuously distributed covariables measured at baseline was presented in Supplementary Table S1 and Supplementary Table S2 for men and women, respectively. In line with that, the characteristics of the participants by sex, age, smoking status and daily alcohol intake was presented in Supplementary Table S3, S4, S5 and S6, respectively.

Renal function changes. Table 4 lists the baseline and follow-up characteristics, and the changes from baseline to follow, in the 653 participants who had a follow-up measurement of renal function. After a median of 4.8 years (5th to 95th percentile interval, 3.7–5.4 years) serum creatinine increased by 3.7 $\mu\text{mol/L}$ ($P<0.0001$) and eGFR decreased by 1.9 mL/min/1.73 m^2 ($P<0.0001$). From baseline to follow-up, eGFR reverted back to a value $>60 \text{ mL/min/1.73 m}^2$ in 7 participants with CKD at baseline and microalbuminuria disappeared in 2. Of the 600 participants with CKD stage ≤ 2 at baseline, 48 progressed to CKD stage ≥ 3 at follow-up ($P=0.0004$); among 549 participants without microalbuminuria at baseline, 9 developed microalbuminuria ($P=0.038$). In longitudinal analyses (Table 5), we accounted for baseline serum creatinine and baseline eGFR by calculating the percent change between the repeat and the first measurement of these biomarkers, while adjusting the mixed models for covariables, including sex, baseline age (linear and square term), socioeconomic class, follow-up duration, baseline body mass index, and the baseline value of and change during follow-up in mean arterial pressure, heart rate, plasma glucose, the total-to-HDL serum cholesterol ratio, γ -glutamyltransferase, smoking status, and the intake of antihypertensive drugs (all drugs combined). The changes in serum creatinine, eGFR and the prevalence of CKD and microalbuminuria were unrelated to BC and $\text{PM}_{2.5}$ (Table 5; $P\geq 0.48$). The geographical associations of the multivariable-adjusted percent change in the eGFR in relation to BC and $\text{PM}_{2.5}$ appear in Figs. 1 and 2, respectively.

The Spearman rank correlation coefficients between percent change in eGFR and the exposure to BC were -0.016 ($P=0.68$) and $+0.20$ ($P=0.52$) in the individual data and in the data aggregated by municipality (Fig. 1).

Characteristic	0.74–1.07 µg/m ³	1.04–1.30 µg/m ³	1.15–1.95 µg/m ³	P
All in category	273	273	274	
Women (n [%])	139 (50.9)	138 (50.6)	139 (50.7)	> 0.99
Smokers (n [%])	45 (16.5)	55 (20.2)	68 (24.8)	0.05
Alcohol intake ≥ 5 g/day (n [%])				
Hypertension (n [%])	112 (41.0)	113 (41.4)	116 (42.3)	0.95
Antihypertensive treatment (n [%])	70 (25.6)	67 (24.5)	74 (27.0)	0.80
Statin treatment (n [%])	40 (14.6)	32 (11.7)	34 (12.4)	0.56
Diabetes mellitus (n [%])	17 (6.2)	7 (2.6)	8 (2.9)	0.07
Cardiovascular disease (n [%])	12 (4.4)	9 (3.2)	18 (6.6)	0.19
Microalbuminuria (n [%])	6 (2.3)	15 (5.8)	8 (3.1)	0.09
CKD, stage ≥ 3 (n [%])	26 (9.5)	23 (8.4)	20 (7.3)	0.64
Mean of characteristic				
Age (years)	51.4 (15.4)	51.3 (15.6)	50.8 (16.0)	0.90
Body mass index (kg/m ²)	26.7 (4.7)	26.3 (3.9)	26.6 (4.4)	0.63
Systolic pressure (mm Hg)	128.5 (17.6)	129.7 (16.9)	129.9 (17.9)	0.58
Diastolic pressure (mm Hg)	79.4 (9.9)	79.8 (9.0)	79.8 (9.7)	0.80
Mean arterial pressure (mm Hg)	95.7 (11.0)	96.5 (10.2)	96.5 (10.7)	0.63
Heart rate (beats per minute)	63.7 (9.9)	63.0 (9.4)	63.8 (9.9)	0.55
Biochemical data				
Serum creatinine (µmol/L)	86.2 (13.5)	86.4 (18.4)	86.8 (14.3)	0.91
eGFR (mL/min/1.73 m ²)	80.6 (16.1)	80.9 (15.9)	81.3 (17.2)	0.88
Total cholesterol (mmol/L)	5.18 (0.92)	5.37 (1.04)*	5.21 (0.94)	0.06
HDL cholesterol (mmol/L)	1.40 (0.33)	1.45 (0.37)	1.43 (0.35)	0.22
Total-to-HDL cholesterol ratio	3.89 (1.02)	3.90 (1.09)	3.81 (0.99)	0.50
Plasma glucose (mmol/L)	5.05 (1.16)	4.91 (0.55)*	4.87 (0.56)	0.03
γ-glutamyltransferase (U/L)	22 (10–63)	2 (11–95)	22 (10–64)	0.89
Airborne particulate				
Black carbon (µg/m ³)	0.99 (0.05)	1.12 (0.06) [§]	1.39 (0.22) [§]	< 0.0001
PM _{2.5} (µg/m ³)	12.7 (0.27)	13.2 (0.34) [§]	14.5 (0.74) [§]	< 0.0001

Table 1. Baseline characteristics of participants by thirds of the black carbon distribution. CKD, chronic kidney disease; eGFR, glomerular filtration rate estimated from serum creatinine by the CKD-EPI formula; HDL, high-density lipoprotein. Microalbuminuria (> 3.5/> 2.5 mg per mmol creatinine in women/men) was available in 780 participants. Thirds of the black carbon distribution were determined after stratification for sex and age (< 50, 50–64, ≥ 65 years). Blood pressure was the average of five consecutive auscultatory readings. Hypertension was a blood pressure of ≥ 140 mm Hg systolic or ≥ 90 mm Hg diastolic, or use of antihypertensive drugs. Diabetes mellitus was a fasting plasma glucose of > 7.0 mmol/L (> 126 mg/dL) or use of antidiabetic agents. The central tendency (data spread) is given as arithmetic mean (SD) or median (5th–5th percentile interval). The central tendency (data spread) is given as arithmetic mean (SD) or median (5th–5th percentile interval). P-values were derived by Fisher exact test, ANOVA or the Kruskal–Wallis test. Significance of the difference with the adjacent lower third: * $P \leq 0.05$; [§] $P \leq 0.0001$.

For the PM_{2.5} exposure, the corresponding estimates were −0.016 ($P = 0.69$) and −0.022 ($P = 0.94$), respectively (Fig. 2).

Sensitivity analyses. The subgroup analyses, dichotomised by sex, age, smoking status and daily alcohol consumption produced consistent results. This was the case for the cross-sectional analyses (Supplementary Table S7 and Supplementary Table S8) and the longitudinal analyses (Supplementary Table S9 and Supplementary Table S10) in relation to BC (Supplementary Table S7 and Supplementary Table S9) and PM_{2.5} (Supplementary Table S8 and Supplementary Table S10). Along similar lines, the cross-section and longitudinal analyses with reduced adjustment were confirmatory (Supplementary Table S11 and Supplementary Table S12). The covariables kept in these analyses were sex, age (linear and squared term) and antihypertensive treatment (all drug classes combined) in the cross-sectional approach. In the longitudinal analyses the covariables were sex, baseline age (linear and square term), follow-up duration and the intake of antihypertensive drugs at baseline and follow-up (all drug classes combined).

Discussion

In the current population study, we evaluated the associations of eGFR and change in eGFR with BC and PM_{2.5}. The prospective analyses demonstrated over nearly 5 years a decline in eGFR of approximately 2 mL/min/1.73 m² and a progression from CKD stage 2 or less to CKD stage 3 or higher in nearly 8% of participants. However,

Characteristic	11.0–13.0 µg/m ³	12.9–13.9 µg/m ³	13.3–16.1 µg/m ³	P
All in category	273	273	274	
Women (n [%])	139 (50.9)	137 (50.2)	140 (51.1)	0.98
Smokers (n [%])	48 (17.6)	49 (18.0)	71 (25.9)*	0.03
Hypertension (n [%])	112 (41.0)	118 (43.2)	111 (40.5)	0.79
Antihypertensive treatment (n [%])	72 (26.4)	66 (24.2)	73 (26.6)	0.78
Statin treatment (n [%])	38 (13.9)	37 (13.6)	31 (11.3)	0.63
Diabetes mellitus (n [%])	17 (6.2)	7 (2.6)	8 (2.9)	0.07
Cardiovascular disease (n [%])	12 (4.4)	12 (4.4)	15 (5.5)	0.79
Microalbuminuria (n [%])	7 (2.7)	13 (5.1)	9 (3.4)	0.34
CKD, stage ≥ 3 (n [%])	26 (9.5)	25 (9.2)	18 (6.6)	0.40
Mean of characteristic				
Age (years)	51.6 (15.4)	51.7 (15.5)	50.2 (16.1)	0.47
Body mass index (kg/m ²)	26.4 (4.3)	26.6 (4.4)	26.6 (4.4)	0.91
Systolic pressure (mm Hg)	128.2 (18.2)	130.7 (17.3)	129.2 (16.9)	0.26
Diastolic pressure (mm Hg)	79.2 (9.7)	80.0 (9.4)	79.9 (9.5)	0.56
Mean arterial pressure (mm Hg)	95.5 (11.1)	96.9 (10.6)	96.3 (10.2)	0.33
Heart rate (beats per minute)	63.5 (9.8)	63.0 (9.1)	64.0 (10.3)	0.46
Biochemical data				
Serum creatinine (µmol/L)	86.3 (13.4)	86.8 (19.3)	86.2 (13.0)	0.88
eGFR (mL/min/1.73 m ²)	80.3 (15.9)	80.5 (16.1)	81.9 (17.2)	0.44
Total cholesterol (mmol/L)	5.19 (0.94)	5.33 (1.01)	5.24 (0.96)	0.24
HDL cholesterol (mmol/L)	1.40 (0.33)	1.42 (0.38)	1.45 (0.34)	0.40
Total-to-HDL cholesterol ratio	3.86 (1.00)	3.95 (1.09)	3.78 (1.00)	0.17
Plasma glucose (mmol/L)	5.04 (1.11)	4.92 (0.63)	4.86 (0.58)	0.03
γ-glutamyltransferase (units/L)	22 (10–67)	21 (10–95)	22 (11–63)	0.56
Airborne particulate				
Black carbon (µg/m ³)	0.99 (0.06)	1.12 (0.07) [§]	1.39 (0.15) [§]	<0.0001
PM _{2.5} (µg/m ³)	12.7 (0.25)	13.2 (0.20) [§]	14.6 (0.70) [§]	<0.0001

Table 2. Baseline characteristics of participants by thirds of the PM_{2.5} distribution. CKD, chronic kidney disease; eGFR, glomerular filtration rate estimated from serum creatinine by the CKD-EPI formula; HDL, high-density lipoprotein. Microalbuminuria (> 3.5/> 2.5 mg per mmol creatinine in women/men) was available in 780 participants. Thirds of the PM_{2.5} distribution were determined after stratification for sex and age (< 50, 50–64, ≥ 65 years). Blood pressure was the average of five consecutive auscultatory readings. Hypertension was a blood pressure of ≥ 140 mm Hg systolic or ≥ 90 mm Hg diastolic, or use of antihypertensive drugs. Diabetes mellitus was a fasting plasma glucose of > 7.0 mmol/L (> 126 mg/dL) or the use of antidiabetic agents. The central tendency (data spread) is given as arithmetic mean (SD) or median (5th–5th percentile interval). *P*-values were derived by Fisher exact test, ANOVA or the Kruskal–Wallis test. Significance of the difference with the adjacent lower third: **P* ≤ 0.05; [§]*P* ≤ 0.0001.

findings with regard to the key research question were negative. There was no association of eGFR, change in eGFR or CKD progression with BC or PM_{2.5}. The current findings contrast with the observation that in the same study cohort (N = 671), systolic left ventricular function was slightly worse (*P* ≤ 0.027) with higher BC and PM_{2.5} exposure with association sizes per interquartile range increment ranging from −0.339 to −0.458% for longitudinal strain and from −0.033 to −0.049 s^{−1} for the longitudinal strain rate¹³. In the Environmental Influence on Early Ageing study (ENVIRONAGE)¹⁴, in 381 mother–offspring pairs, an interquartile range increment in PM_{2.5} exposure over the entire pregnancy was positively associated with mitochondrial DNA methylation (*MT-RNR1*: +0.91%, *P* = 0.01 and D-loop: +0.21%, *P* = 0.05) and inversely associated with mitochondrial DNA content in placental tissue (relative change of −15.6%, *P* = 0.001). Taken together, these divergent findings must be interpreted within the context of the circulatory kinetics of the ultrafine particulate. The PM_{2.5} fraction and the nano-sized BC particles readily penetrate the air–blood barrier in the lung alveoli and are subsequently dispersed body wide, as evidenced by the detection of BC particles in urine⁴. However, the heart is the first target organ on the circulatory path of these toxic particles. The uterine arteries are tributaries branching off directly from the internal iliac artery. At term, maternal blood flow to the placenta is within the 600–700 mL/min range and the length of the foetal capillaries is close to 320 kilometres¹⁵. The renal blood flow represents 20% of cardiac output, but over 90% of the renal blood flow is distributed to the cortex¹⁶. These haemodynamic properties, the downstream dilution of the toxic particles from their point of entry into the circulation, and the capillary surface exposed probably explain the divergent vulnerability of organs.

Particulate matter is a mixture of solid and liquid particles in the air¹⁷. Most previous studies focused on PM₁₀^{5–12}. In 3901 participants enrolled in the Multi-Ethnic Study of Atherosclerosis, the urinary

Airborne particulate Renal function	Baseline only (n = 820)		Follow-up only (n = 653)		Baseline and follow-up (n = 820)	
	Estimate (95% CI)	P	Estimate (95% CI)	P	Estimate (95% CI)	P
Black carbon						
Serum creatinine ($\mu\text{mol/L}$)	0.35 (−0.93 to 1.64)	0.59	0.29 (−1.84 to 2.42)	0.79	0.39 (−1.08 to 1.85)	0.61
eGFR (mL/min/1.73 m^2)	−0.08 (−1.25 to 1.09)	0.90	−0.37 (−1.85 to 1.10)	0.62	−0.04 (−1.20 to 1.12)	0.95
Prevalence						
Chronic kidney disease (OR)	−0.09 (−0.43, 0.24)	0.59	0.12 (−0.22 to 0.45)	0.49	0.03 (−0.25 to 0.31)	0.85
Microalbuminuria (OR)	0.20 (−0.35 to 0.75)	0.48	0.15 (−0.40 to 0.71)	0.59	0.23 (−0.22 to 0.67)	0.32
PM_{2.5}						
Serum creatinine ($\mu\text{mol/L}$)	0.23 (−1.07 to 1.52)	0.73	0.10 (−2.03 to 2.23)	0.93	0.28 (−1.19, 1.75)	0.71
eGFR (mL/min/1.73 m^2)	0.00 (−1.18 to 1.19)	0.99	−0.30 (−1.78 to 1.18)	0.69	0.01 (−1.16 to 1.17)	0.99
Prevalence						
Chronic kidney disease (OR)	−0.09 (−0.42 to 0.24)	0.59	0.04 (−0.29 to 0.38)	0.81	−0.01 (−0.29 to 0.26)	0.94
Microalbuminuria (OR)	0.27 (−0.26 to 0.79)	0.32	0.06 (−0.43 to 0.54)	0.82	0.21 (−0.19 to 0.61)	0.31

Table 3. Multivariable-adjusted cross-sectional associations of renal function with exposure to black carbon and PM_{2.5}. eGFR is the glomerular filtration rate estimated from serum creatinine by the CKD-EPI formula. Association sizes were derived from mixed models, which accounted for clustering of the baseline and follow-up data among participants living at the same address. For chronic kidney disease (eGFR < 60 mL/min/1.73 m²) and microalbuminuria (> 3.5/> 2.5 mg per mmol creatinine in women/men), association sizes are expressed as odds ratios (OR). Models were adjusted for sex, age (linear and squared term), mean arterial pressure, heart rate, body mass index, plasma glucose, total-to-HDL cholesterol ratio, γ -glutamyltransferase, smoking, daily energy expenditure in physical activity, socioeconomic class, and antihypertensive treatment (by drug class). Association sizes, given with 95% confidence interval, were expressed for an interquartile range increment in the airborne particulate.

albumin-to-creatinine ratio was measured at three visits 1.5 to 2 years apart from baseline (2000–2004) and correlated with PM₁₀ as measured by ambient air pollution monitors over 1 month, 2 months and 20 years before the first visit, with adjustments applied for race/ethnicity, sex, age smoking, second-hand smoking, body mass index and dietary protein intake. The study did not demonstrate a significant association between prevalent microalbuminuria or accelerated development of microalbuminuria in relation to PM₁₀¹¹. In contrast, among 1103 consecutive Boston-area patients hospitalised with acute ischaemic stroke between 1999 and 2004, eGFR was correlated with residential distance to major roadways ranging from 50 m or less to over 1 km with adjustments applied for race, sex, age, smoking, comorbid conditions, treatment with angiotensin-converting enzyme inhibitors, and neighbourhood-level socioeconomic status⁵. Patients living closer to a major roadway had lower eGFR than patients living farther away (P for trend = 0.01). Patients living at a distance of 50 m vs. 1 km had a 3.9 mL/min/1.73 m² lower eGFR (P = 0.007)⁵. Among 21,656 residents of Taipei (2007–2009)⁷, eGFR and the prevalence of CKD (eGFR < 60 mL/min/1.73 m²) were correlated with PM_{coarse}, PM₁₀ and PM_{2.5} with adjustments applied for sex, age, body mass index, hypertension (categorical), fasting blood glucose, total serum cholesterol, smoking and drinking, educational attainment, and distance to a major road (continuous). eGFR was 0.69 mL/min/1.73 m² lower per interquartile range increment in PM₁₀ (5.83 $\mu\text{g}/\text{m}^3$), while the odds of having CKD were 1.15 times higher for the same increment in PM₁₀⁷. The corresponding estimates for PM_{coarse} (6.59 $\mu\text{g}/\text{m}^3$) were −1.07 mL/min/1.73 m² for eGFR and 1.26 for CKD. In contrast to the associations with PM₁₀ and coarse PM, those with PM_{2.5} did not reach statistical significance⁷.

Human studies relating renal function to exposure to PM_{2.5} reported conflicting results^{6,7,9,10}. In the cross-sectional Taiwanese study reviewed above⁷, there was no association between eGFR or CKD with PM_{2.5} (annual average concentration, 26.6 $\mu\text{g}/\text{m}^3$). In a longitudinal analysis of 669 men enrolled in the Veterans Administration Normative Aging Study with up to four visits between 2000 and 2011 (n = 1715 visits)⁶, 1-year exposure to PM_{2.5} prior to each visit was assessed using a validated spatiotemporal model that utilised satellite remote-sensing aerosol optical depth data. In all person-visits by calendar year, the mean yearly average PM_{2.5} concentrations increased from 10.5 $\mu\text{g}/\text{m}^3$ in 2000 to their highest level of 11.8 $\mu\text{g}/\text{m}^3$ in 2002 and later decreased to less than 9.0 $\mu\text{g}/\text{m}^3$ in 2010 and 2011. eGFR was analysed by time-varying linear mixed-effects regression models as continuous function of the 1-year PM_{2.5} levels, while adjusting for a large number of covariables. A 2.1- $\mu\text{g}/\text{m}^3$ (interquartile range) higher 1-year PM_{2.5} was associated with a 1.87 mL/min/1.73 m² lower eGFR (95% confidence interval, 0.76–2.99 mL/min/1.73 m²). A 2.1 $\mu\text{g}/\text{m}^3$ higher 1-year PM_{2.5} was also associated with an additional annual decrease in eGFR of 0.60 mL/min/1.73 m² per year (95% confidence interval, 0.40–0.79 mL/min/1.73 m²). A recent study linked the Environmental Protection Agency and the Department of Veterans Affairs databases to build an observational cohort of 2,482,737 United States veterans¹⁰. It applied survival models to evaluate the association of PM_{2.5} concentrations and risk of incident CKD and end-stage renal disease¹⁰. County-level exposure was defined at baseline as the annual average PM_{2.5} concentrations in 2004, and as a time-varying variable updated annually and as cohort participants moved. In analyses of baseline exposure (median, 11.8 $\mu\text{g}/\text{m}^3$ [interquartile range 10.1–13.7 $\mu\text{g}/\text{m}^3$]), a 10- $\mu\text{g}/\text{m}^3$ increase in PM_{2.5} concentration was associated with a 20% to 30% increase in the risk of CKD and end-stage renal dysfunction. The time-varying analyses produced

Characteristic	Baseline 2005–2009	Follow-up 2009–2013	Change 95% CI
Number with characteristic			
Women (n [%])	328 (50.2)	328 (50.2)	–
Smokers (n [%])	124 (19.0)	98 (15.0)	– 4.0 (– 5.6, – 2.3) [§]
Alcohol intake ≥ 5 g/day (n [%])			
Hypertension (n [%])	268 (41.0)	335 (51.3)	10.3 (7.0, 13.5) [§]
Antihypertensive treatment (n [%])	163 (25.0)	212 (32.5)	7.5 (5.1, 9.9) [§]
Diabetes mellitus (n [%])	23 (3.5)	43 (6.6)	3.1 (1.7, 4.4) [§]
CKD, stage ≥ 3 (n [%])	53 (8.2)	94 (14.4)	6.2 (4.1, 8.5) [§]
Microalbuminuria (n [%])	17 (3.0)	24 (4.2)	1.2 (0.05, 2.6)*
Mean of characteristic			
Age (years)	50.9 (14.7)	55.6 (14.6)	4.7 (4.7, 4.8) [§]
Body mass index (kg/m ²)	26.5 (4.4)	27.3 (4.4)	0.7 (0.6, 0.9) [§]
Systolic pressure	128.7 (16.7)	132.2 (16.8)	3.5 (2.4, 4.6) [§]
Diastolic pressure	79.8 (9.4)	82.3 (9.7)	2.5 (1.8, 3.2) [§]
Mean arterial pressure	96.1 (10.3)	98.9 (10.1)	2.8 (2.1, 3.5) [§]
Heart rate (beats per minute)	62.7 (9.4)	62.2 (9.7)	– 0.5 (– 1.3, 0.3)
Biochemical data			
Serum creatinine (μ mol/L)	86.4 (15.5)	90.0 (22.7)	3.7 (2.6, 4.7) [§]
eGFR (mL/min/1.73 m ²)	80.9 (15.4)	79.0 (18.1)	– 1.9 (– 2.8, – 1.0) [§]
Total cholesterol (mmol/L)	5.3 (0.96)	5.0 (0.95)	– 0.25 (– 0.32, – 0.18) [§]
HDL-cholesterol (mmol/L)	1.43 (0.35)	1.45 (0.38)	0.02 (0.01, 0.04)*
Total-to-HDL cholesterol ratio	3.85 (1.01)	3.68 (1.24)	– 0.15 (– 0.32, 0.02)
Plasma glucose (mmol/L)	4.94 (0.83)	4.96 (0.79)	– 0.00 (– 0.08, 0.07)
γ -glutamyltransferase (U/L)	23.3 (10–69)	24.7 (11–72)	3.7 (0.3, 7.2)*

Table 4. Baseline and follow-up characteristics of 653 participants. CKD, chronic kidney disease; eGFR, estimated glomerular filtration rate derived from serum creatinine by the CKD-EPI formula; HDL, high-density lipoprotein. Blood pressure was the average of five consecutive auscultatory readings. Hypertension was a blood pressure of ≥ 140 mm Hg systolic or ≥ 90 mm Hg diastolic, or use of antihypertensive drugs. Diabetes mellitus was a fasting plasma glucose of > 7.0 mmol/L (> 126 mg/dL) or use of antidiabetic agents. The assessment of microalbuminuria ($> 3.5/ > 2.5$ mg per mmol creatinine in women/men) was available in 566 participants. The central tendency (data spread) is given as arithmetic mean (SD) or median (5th–5th percentile interval). For categorical variables, percentage change is given. Significance of the change from baseline to follow-up (95% confidence interval): * $P \leq 0.05$; $^{\dagger}P \leq 0.01$; $^{\ddagger}P < 0.001$; $^{\S}P \leq 0.0001$.

Renal function trait	N	Black carbon		PM _{2.5}	
		Estimate (95% CI)	P	Estimate (95% CI)	P
Continuous outcomes					
Serum creatinine (%)	653	0.10 (− 1.55 to 1.76)	0.90	0.25 (− 1.42, 1.92)	0.77
eGFR (%)	653	− 0.45 (− 1.92, 1.00)	0.54	− 0.53 (− 1.99, 0.93)	0.48
Incidence					
CKD (OR)	48/600	0.13 (− 0.25 to 0.50)	0.51	0.02 (− 0.36 to 0.39)	0.93
Microalbuminuria (OR)	9/549	0.09 (− 0.99 to 1.16)	0.88	0.06 (− 0.84 to 0.95)	0.90

Table 5. Multivariable-adjusted associations between changes from baseline to follow-up in renal function and in the exposure to airborne particulate. eGFR is the glomerular filtration rate estimated from serum creatinine by the CKD-EPI formula. For continuously distributed variables (serum creatinine and eGFR), changes were computed as the follow-up minus baseline values and expressed as a percentage of the baseline value. Incidence refers to new-onset chronic kidney disease (< 60 mL/min/1.73 m²). N indicates the number of participants in the analysis or the number of new-onset cases/number of participants at risk. Associations accounted for clustering of data among participants living at the same address and were adjusted for sex, baseline age (linear and square term), socioeconomic class, follow-up duration, baseline body mass index, and the baseline value of and change during follow-up in mean arterial pressure, heart rate, plasma glucose, the total-to-HDL serum cholesterol ratio, γ -glutamyltransferase, smoking status, and the intake of antihypertensive drugs (all drugs combined). Association sizes were expressed for an interquartile range increment in the airborne particulate.

Figure 1. Geographical associations of the multivariable-adjusted percent change in the glomerular filtration rate estimated from serum creatinine (ΔeGFR) at the individual level (A) or aggregated per municipality (B) with black carbon air pollution contours. Grey lines indicate borders of municipalities. Red lines represent the air pollution contours of major roads. The Spearman rank correlation coefficients between percent change in eGFR and the exposure to BC were -0.016 ($P=0.68$) and 0.200 ($P=0.52$) in the individual and aggregated data, respectively.

similar results¹⁰. A Chinese study of 71,151 renal biopsies involving 282 cities with standardisation for age and region identified IgA nephropathy (28.1%) and membranous nephropathy (23.1%) as the leading causes of nephropathy⁹. Three-year average $\text{PM}_{2.5}$ exposure varied among the 282 cities, ranging from 6 to $114 \mu\text{g}/\text{m}^3$ (mean, $52.6 \mu\text{g}/\text{m}^3$). Each $10\text{-mg}/\text{m}^3$ increase in the $\text{PM}_{2.5}$ concentration was associated with 14% higher odds for membranous nephropathy⁹ (odds ratio, 1.14; 95% confidence interval, 1.10–1.18) in regions with $\text{PM}_{2.5}$ concentration in excess of $70 \mu\text{g}/\text{m}^3$.

Strengths and limitations. In our current study, we related the renal health outcomes of individual study participants with subject-level estimates of exposure to ultrafine particulate matter. This approach mitigates the so-called ecological fallacy, which arises when aggregate measures of outcome, e.g., cancer incidence by municipality are associated with aggregate estimates of exposure¹⁸, an approach applied in several previous studies of the renal responses to exposure to $\text{PM}_{2.5}$. Our study is the first to address renal outcomes in relation to BC. Furthermore, our cohort study was population based and therefore representative for exposure, housing conditions and lifestyle in an affluent West-European country. Our study included cross-sectional and longitudinal analyses, both adjusted for a wide range of confounders, in the longitudinal analyses in a time-dependent manner. Sensitivity analyses stratified for various subgroups and minimally adjusted analyses were confirmatory. Notwithstanding these strong points, our study must also be interpreted within the context of its potential limitations. First, the sample size of the study population was relatively small compared with other studies of renal function in relation to $\text{PM}_{2.5}$ ^{9,10}. Second, due to a change in methodology, serum creatinine was measured by slightly different methods in 536 of 653 participants (82.1%) at baseline and follow-up. However, as reported previously¹⁹, the difference in the annual decrease in eGFR between participants who had their serum creatinine measured by different compared with the same method averaged only $0.05 \text{ mL}/\text{min}/1.73 \text{ m}^2$ ($P=0.60$). Moreover, whatever creatinine assay was used, the annual eGFR decrease was similar as that observed in other European population studies²⁰. Third, as in previous studies of chronic air pollution²¹, the assessment of renal function and the collection of the air pollution data was not done simultaneously. On the other hand, we used high-resolution spatial data. Several studies in the Netherlands²², Italy (Rome)²³, the UK²⁴, and Canada (Vancouver)²⁵ demonstrated that the land use models applied in our current study are representative for the air pollution

Figure 2. Geographical associations of the multivariable-adjusted percent change in the glomerular filtration rate estimated from serum creatinine ($\Delta eGFR$) at the individual level (A) or aggregated per municipality (B) with $PM_{2.5}$ air pollution contours. Grey lines indicate borders of municipalities. Red lines represent the air pollution contours of major roads. The Spearman rank correlation coefficients between percent change in $eGFR$ and the exposure to $PM_{2.5}$ were -0.016 ($P=0.69$) and -0.022 ($P=0.94$) in the individual and aggregated data, respectively.

over periods of 10 years or longer prior to the actual modelling^{22–25}. Fourth, the incidence of microalbuminuria was low, precluding subgroup analyses for this endpoint. The data given in Table 5 including all data available in the whole study cohort are therefore only given as an exploratory result. Finally, the prevalence of previous cardiovascular disease and diabetes in our study participants was low, precluding extrapolation of our current findings to patients with comorbidities, who might be more vulnerable with regard to the renal responses to exposure to ultrafine toxic particulate.

Methods

Study population. The Flemish Study on Environment, Genes and Health Outcomes (FLEMENGHO) complies with the Helsinki declaration²⁶ and is registered at the Belgian Data Protection Authority (reference number III 11/1234/13, dated 22 August 2013). The ethics committee of the University Hospital Leuven, Belgium, approved secondary use of FLEMENGHO data (national registration number, B32220083510). From August 1985 until November 1990, a random sample of the households, stratified for sex and age (20–39, 40–59, and ≥ 60 years) and living in a geographically defined area of Northern Belgium (Figs. 1, 2) was investigated. All household members with a minimum age of 20 years were invited to take part. From June 1996 until January 2004 recruitment of families continued, using the former participants (1985–1990) as index persons and also including teenagers^{13,27}. The initial participation rate at enrolment was 78%. The informed consent was obtained from all participants.

Participants were repeatedly followed-up. From 2005 to 2009, we invited 1031 surviving participants, who still resided in the catchment area of the study (North Limburg, Belgium) and who had not been institutionalised. Of these, 828 renewed informed consent (participation rate, 80.3%). We excluded 8 participants, because their renal function had not been assessed. Of 820 participants examined at baseline, 653 took part in a follow-up assessment of their renal function on average 4.7 years (5th–95th percentile, 3.7–5.4 years) later^{13,19,27}. Therefore, the number of participants available for the cross-sectional and longitudinal analyses totalled 820 and 653, respectively.

Clinical measurements. Blood pressure (continuous) was the average of five consecutive auscultatory readings obtained after participants had rested for 5 min in the sitting position. Mean arterial pressure (continuous) was diastolic blood pressure plus one third of pulse pressure (the difference between systolic and diastolic blood pressure). Hypertension (categorical) was a blood pressure of ≥ 140 mm Hg systolic, or ≥ 90 mm Hg diastolic, or use of antihypertensive drugs. Antihypertensive drugs were classified (categorical) as diuretics (thiazides, loop diuretics and aldosterone antagonists), inhibitors of the renin-angiotensin system (β -blockers, angiotensin-converting enzyme inhibitors and angiotensin type-1 receptor antagonists), and vasodilators (calcium-channel blockers and α -blockers). Body mass index (continuous) was weight (kilogram) divided by height (metre) squared.

The study nurses also administered a standardised questionnaire inquiring into each participant's medical history, smoking and drinking habits, intake of medications, habitual physical activity during leisure time and at work, and socioeconomic status. Smoking was the current use of any smoking materials on a daily basis (categorical). The amount of alcohol consumed expressed in gram per day was computed from the self-reported frequency and type of alcoholic beverages used (beer, wine, fortified wine and liquor) and their alcohol content (6, 13, 18 and 40 volumetric percentages, respectively)²⁸. Participants with a daily alcohol consumption of 5 g/day or more were categorised as drinkers.

Socioeconomic status was coded according to the complex scales provided by the UK Office of Population Censuses and Surveys²⁹, and simplified into a linear scale with scores ranging from 1 to 3³⁰. Using validated questionnaires²⁸ and published tables³¹, we computed the energy spent in physical activity (continuous) from body weight, time devoted to work, walking, sports and leisure time activities, and type of physical activity. This covariable was introduced, because of the known associations of eGFR^{32,33} and albuminuria^{32,34} with strenuous physical activity.

Biochemical measurements. Venous blood samples were obtained after 8 h fasting. Participants collected a 24-h urine sample. After centrifugation and aliquoting, blood-derived specimens were stored at -80°C and 10-ml urine samples at -40°C . A single certified laboratory did the routine biochemistry, using quality-controlled automated methods. Blood samples were analysed for plasma glucose and total and high-density lipoprotein (HDL) serum cholesterol, serum creatinine and serum γ -glutamyltransferase (biomarker of alcohol intake). Diabetes mellitus was a fasting glucose exceeding 7.0 mmol/L (126 mg/dL) or use of antidiabetic agents. eGFR was calculated based on the Chronic Kidney Disease Epidemiology Collaboration (CKD-EPI) equation³⁵, using age, sex and serum creatinine. The single laboratory involved in measuring the serum creatinine concentration in our study implemented the IDMS-traceable (isotope-dilution mass spectrometry) creatinine assay³⁶, starting from 18 December 2008. Of the baseline creatinine measurements 703 (85.7%) were done before this date. The remaining 117 baseline measurements and all 653 follow-up measurements were done after 18 December 2008. The urine samples were analysed for microalbumin and creatinine. CKD was staged following the National Kidney Foundation (KDOQI) guideline³⁷. Microalbuminuria was defined by an albumin-to-creatinine ratio of at least 3.5 mg/mmol in women or 2.5 mg/mmol in men³⁸. A single blood and urine sample were used to determine the CKD endpoint in categorical analyses, defined as an eGFR of 60 mL/min/1.73 m², in line with our previous research^{19,27} and landmark population studies^{39,40}.

Ambient air pollution. Particulate matter is the sum of all solid and liquid particles suspended in air¹⁷. PM_{2.5} has an aerodynamic diameter of less than 2.5 μm . Upon inhalation, PM_{2.5} reaches the smallest airways and alveoli and can even cross the blood-air barrier and directly penetrate into the blood stream. BC is a component of PM_{2.5}, consists of pure carbon in several bond forms, and finds its origin in the incomplete combustion of fossil fuels, biofuel or biomass.

In the current study, BC and PM_{2.5} exposure ($\mu\text{g}/\text{m}^3$) were calculated for each participant's residential address at the time of the air quality measurements (2010–2014), using a high resolution spatiotemporal interpolation method^{41,42} that takes into account land-cover data obtained from satellite images (CORINE database [http://www.eea.europa.eu/publications/COR0-landcover/at_download/file]) and pollution data of fixed monitoring stations in combination with a dispersion model^{41,42}. This approach provides daily exposure values in a dense irregular receptor grid, using input from the Belgian telemetric air quality networks and emissions from point and line sources. The air quality network includes 14 monitoring stations for black carbon and 34 for PM_{2.5}. Models covered data averaged over a 5-year period (2010–2014), which reflect the long-term spatial air pollution and are representative for earlier periods^{22–25}. Model performance was evaluated by leave-one-out cross-validation across monitoring stations. The spatiotemporal explained variance was nearly 80%^{41,42} for BC and PM_{2.5}.

Statistical analysis. For database management and statistical analysis, we used the SAS system, version 9.4 (SAS Institute Inc., Cary, NC). Departure from normality was evaluated by Shapiro–Wilk's statistic. We normalised the distributions of γ -glutamyltransferase, and the daily energy expenditure in physical activity by a logarithmic transformation. In between-group analyses, means were compared using the large-sample z-test, ANOVA and proportions by Fisher's exact test. Longitudinal changes were assessed by a t-statistic of the distributions of the follow-up minus baseline values for continuous variables and by the McNemar test for categorical variables. We rank normalised the distribution of BC and PM_{2.5} by sorting the measurements from the smallest to the largest and then applying the inverse cumulative normal function. We computed Pearson correlation coefficients between continuously distributed data and Spearman rank correlations to assess the association between geocorrelation between percentage changes in eGFR and the exposure to BC and PM_{2.5}.

For the cross-sectional analysis, the association of renal function measures with air pollution was assessed by a generalised linear mixed model adjusting for residential clustering of participants (sharing the same address)

as random effect and with adjustments applied for relevant covariables^{43,44}. The covariables in the cross-sectional analyses included: sex, age (linear and squared term), mean arterial pressure, heart rate, body mass index, plasma glucose, total-to-HDL cholesterol ratio, γ -glutamyltransferase as biomarker of alcohol consumption, smoking, daily energy expenditure in physical activity, socioeconomic class, and antihypertensive treatment (by drug class). In longitudinal analyses of 653 participants, we accounted for baseline serum creatinine and baseline eGFR by calculating the percent change between the repeat and the first measurement of these biomarkers, while adjusting for sex, baseline age (linear and square term), socioeconomic class, follow-up duration, baseline body mass index, and the baseline value of and change during follow-up in mean arterial pressure, heart rate, plasma glucose, the total-to-HDL serum cholesterol ratio, γ -glutamyltransferase, smoking status, and the intake of antihypertensive drugs (all drugs combined). The association of the prevalence (cross-sectional analyses) or incidence (longitudinal analyses) of CKD and microalbuminuria with the exposure to particulate were derived by mixed models and expressed as odds ratios, adjusted as outlined above.

In sensitivity analyses, we stratified the participants according to sex, age (< 60 vs. $\geq$ 60 years), smoking status (non-smokers versus smokers), and the amount of alcohol consumed per day (< 5 vs. $\geq$ 5 g). In addition, we re-ran the cross-sectional and longitudinal analyses, while adjusting for a reduced set of covariables, thereby removing potential mediators of renal function decline.

Ethical approval. The Flemish Study on Environment, Genes and Health Outcomes complies with the Helsinki declaration and is registered at the Belgian Data Protection Authority (reference number III 11/1234/13, dated 22 August 2013). The ethics committee of the University Hospital Leuven, Belgium, approved the study (national registration number: B32220083510).

Data sharing. Anonymised participants data will be made available upon request directed to the corresponding author. Proposals will be reviewed and approved by the authors with scientific merit and feasibility as sole criteria. After approval of a proposal, data can be shared via a secure online platform after signing a data access and confidentiality agreement. All data will be made available for a minimum of 5 years from the end of the study.

Conclusions

Exposure to polluted air, in contrast to smoking, is unintentional and adversely affects health in multiple ways, so that prevention is of paramount importance and global efforts to improve air quality should continue. What our current study adds is that at current exposure levels in a semirural area of Flanders renal function is not associated with ultrafine particulate, including BC, in predominantly healthy people representative of the general population.

Received: 23 January 2021; Accepted: 30 June 2021

Published online: 19 July 2021

References

- Wang, H. *et al.* Age-specific and sex-specific mortality in 187 countries, 1970–2010: a systematic analysis for the Global Burden of Disease Study 2010. *Lancet* **380**, 2071–2094 (2012).
- GBD 2017 Risk Factor Collaborators. Global, regional, and national comparative risk assessment of 84 behavioural, environmental and occupational, and metabolic risk factors or clusters of risks for 195 countries and territories, 1990–2017: a systematic analysis for the Global Burden of Disease Study 2017. *Lancet*. 2018; **392**, 1923–1994.
- Yang, B., Guo, J. & Xiao, C. Effect of PM_{2.5} environmental pollution on rat lung. *Environ. Sci. Pollut. Res.* **25**, 36136–36146 (2018).
- Saenen, N. D. *et al.* Children's urinary environmental carbon load. A novel marker reflecting residential ambient air pollution exposure?. *Am. J. Respir. Crit. Care Med.* **196**, 873–881 (2017).
- Lue, S. H., Wellenius, G. A., Wilker, E. H., Mostofsky, E. & Mittleman, M. A. Residential proximity to major roadways and renal function. *J. Epidemiol. Community Health* **67**, 629–634 (2013).
- Mehta, A. J. *et al.* Long-term exposure to ambient fine particulate matter and renal function in older men: The Veterans Administration Normative Aging Study. *Environ. Health Perspect.* **124**, 1353–1360 (2016).
- Yang, Y. R., Chen, Y. M., Chen, S. Y. & Chan, C. C. Associations between long-term particulate matter exposure and adult renal function in the Taipei metropolitan area. *Environ. Health Perspect.* **125**, 602–607 (2017).
- Bowe, B. *et al.* Associations of ambient coarse particulate matter, nitrogen dioxide, and carbon monoxide with the risk of kidney disease: a cohort study. *Lancet Plan Health.* **1**, e267–e276 (2018).
- Xu, X. *et al.* Long-term exposure to air pollution and increased risk of membranous nephropathy in China. *J. Am. Soc. Nephrol.* **27**, 3739–3746 (2016).
- Bowe, B. *et al.* Particulate matter air pollution and the risk of incident CKD and progression to ESRD. *J. Am. Soc. Nephrol.* **29**, 218–230 (2018).
- O'Neill, M. S. *et al.* Airborne particulate matter exposure and urinary albumin excretion: the Multi-Ethnic Study of Atherosclerosis. *Occup. Environ. Med.* **65**, 534–540 (2008).
- Raaschou-Nielsen, O. *et al.* Outdoor air pollution and risk for kidney parenchyma cancer in 14 European cohorts. *Int. J. Cancer.* **140**, 1528–1537 (2017).
- Yang, W. Y. *et al.* Left ventricular function in relation to chronic residential air pollution in a general population. *Eur. J. Prev. Cardiol.* **24**, 1416–1428 (2017).
- Janssen, B. G. *et al.* Placental mitochondrial methylation and exposure to airborne particulate matter in the early life environment: an ENVIRONAGE birth cohort study. *Epigenetics* **10**, 536–544 (2015).
- Mayhew, T. M. Fetoplacental angiogenesis during gestation is biphasic, longitudinal and occurs by proliferation and remodelling of vascular endothelial cells. *Placenta* **23**, 742–750 (2002).
- Pilkington, L. A., Binder, R., de Haas, J. C. M. & Pitts, R. F. Intrarenal distribution of blood flow. *Am. J. Physiol.* **208**, 1107–1113 (1965).

17. Sýkorová, B., Kucbel, M. & Raclavsky, K. Composition of airborne particulate matter in the industrial area versus mountain area. *Perspect. Sci.* **7**, 369–372 (2016).
18. Nawrot, T., Roels, H., Vangronsveld, J. & Staessen, J. A. Cadmium from zinc smelter emission and variation in cancer incidence: the hierarchy of evidence. *Eur. J. Cancer Prevent.* **21**, 497–498 (2012).
19. Wei, F. F. *et al.* Desphospho-uncarboxylated matrix Gla protein is a novel circulating biomarker predicting deterioration of renal function in the general population. *Nephrol. Dial. Transplant.* **33**, 1122–1128 (2018).
20. Guessous, I. *et al.* Serum 25-hydroxyvitamin D level and kidney function decline in a Swiss general adult population. *Clin. J. Am. Soc. Nephrol.* **10**, 1162–1169 (2015).
21. Ruttens, D. *et al.* An association of particulate air pollution and traffic exposure with mortality after lung transplantation in Europe. *Eur. Respir. J.* **49**, 1600484 (2017).
22. Brauer, M. *et al.* Estimating long-term average particulate concentrations: application of traffic indicators and geographic information systems. *Epidemiology* **14**, 228–239 (2003).
23. Rosenlund, M. *et al.* Comparison of regression models with land-use and emissions data to predict the spatial distribution of traffic-related air pollution in Rome. *J. Expos. Sci. Environ. Epidemiol.* **18**, 192–199 (2008).
24. Briggs, D. *et al.* A regression-based method for mapping traffic-related air pollution: Application and testing in four contrasting urban environments. *Sci. Total Environ.* **253**, 151–167 (2000).
25. Henderson, S. B., Beckerman, B., Jerrett, M. & Brauer, M. Application of land use regression to estimate long-term of concentrations of traffic-related nitrogen oxides and fine particulate matter. *Environ. Sci. Technol.* **41**, 2422–2428 (2007).
26. World Medical Association. World Medical Association Declaration of Helsinki. Ethical principles for medical research involving human subjects. *J Am Med Assoc.* 2013; **310**, 2191–2194.
27. Zhang, Z. Y. *et al.* A urinary fragment of mucin-1 subunit α is a novel biomarker associated with renal dysfunction in the general population. *KI Rep.* **2**, 811–820 (2017).
28. Staessen, J. A., Fagard, R. & Amery, A. Life style as a determinant of blood pressure in the general population. *Am. J. Hypertens.* **7**, 685–694 (1994).
29. Office of Population Census and Surveys. *Classification of Occupations and Coding Index*. Governmental Statistical Service, London, 1980 (ISBN: 0-11-6907282).
30. Staessen, J. A. *et al.* Life style as blood pressure determinant. *J. Royal. Sci. Med.* **89**, 484–489 (1993).
31. Åstrand, P. O. & Rodahl, K. *Textbook of Work Physiology Physiological Bases of Exercise* 486–522 (McGraw-Hill Book Company, 1986).
32. Poortmans, J. R. & Ouchinsky, M. Glomerular filtration rate and albumin excretion after maximal exercise in aging sedentary and active men. *J. Gerontol. A Biol. Sci. Med. Sci.* **61**, 1181–1185 (2006).
33. Mingels, A., Jacobs, L., Kleijnen, V., Wodzig, W. & van Dieijen-Visser, M. Cystatin C a marker for renal function after exercise. *Int. J. Sports Med.* **30**, 668–671 (2009).
34. Beetham, K. S., Howden, E. J., Isbel, N. M. & Coombes, J. S. Agreement between cystatin-C and creatinine based eGFR estimates after a 12-month exercise intervention in patients with chronic kidney disease. *BMC Nephrol.* **19**, 366 (2018).
35. Levey, A. S. *et al.* A more accurate method to estimate glomerular filtration rate from serum creatinine: a new prediction equation. *Ann. Intern. Med.* **130**, 461–470 (1999).
36. Myers, G. L. *et al.* Recommendations for improving serum creatinine measurement: a report from the laboratory working group of the National Kidney Disease Education Program. *Clin. Chem.* **52**, 5–18 (2006).
37. National Kidney Foundation. KDOQI clinical practice guidelines for diabetes and CKD: 2012 update. *Am. J. Kidney Dis.* **60**, 850–886 (2012).
38. Williams, B. *et al.* 2018 ESC/ESH guidelines for the management of arterial hypertension. *Eur. Heart J.* **39**, 3021–3104 (2018).
39. Fox, C. S. *et al.* Predictors of new-onset kidney disease in a community-based population. *J. Am. Med. Assoc.* **291**, 844–850 (2004).
40. Fox, C. S. *et al.* A multi-marker approach to predict incident CKD and microalbuminuria. *J. Am. Soc. Nephrol.* **21**, 2143–2149 (2010).
41. Scobioala, S. *et al.* Up-regulation of nestin in the infarcted myocardium potentially indicates differentiation of resident cardiac stem cells into various lineages including cardiomyocytes. *FASEB J.* **22**, 1021–1031 (2008).
42. Lefebvre, W. *et al.* Validation of the MIMOSA-AURORA-IFDM model chain for policy support: modeling concentrations of elemental carbon in Flanders. *Atmos Environ.* **45**, 6705–6713 (2011).
43. Gu, Y. M. *et al.* The urinary proteome as correlate and predictor of renal function in a population study. *Nephrol. Dial. Transplant.* **29**, 2260–2268 (2014).
44. Feng, Y. M. *et al.* Glomerular function in relation to circulating adhesion molecules and inflammation markers in a general population. *Nephrol. Dial. Transplant.* **33**, 426–435 (2018).

Acknowledgements

The authors gratefully acknowledge the expert clerical assistance of Vera De Leebeeck and Renilde Wolfs, Research Unit Hypertension and Cardiovascular Epidemiology, KU Leuven Department of Cardiovascular Sciences, University of Leuven, Belgium.

Author contributions

Y.F. and J.S. designed the study, performed the analysis and drafted the manuscript; L.T., Z.Z., W.Y., F.W., E.B., B.J. and T.N. collected the data and participated the analysis. All authors have read and approved the final manuscript.

Funding

FLEMENGHO was supported by the European Union (Grants IC15-CT98-0329-EPOGH, LSHM CT 037093-InGenious HyperCare, HEALTH-201550-HyperGenes, HEALTH-278249-EU-MASCARA, HEALTH-305507 HOMAGE), the European Research Council (Advanced Researcher Grant-2011–294713-EPLORE and Proof-of-Concept Grant-713601 uPROPHET), the European Research Area Net for Cardiovascular Diseases (JTC2017-046-PROACT), and the Research Foundation Flanders, Ministry of the Flemish Community, Brussels, Belgium. APPREMED (URL: <http://www.appremed.org>) received a non-binding grant from OMRON Healthcare Co., Ltd., Kyoto, Japan. The National Science Fund in China (Grant Numbers: 81470566 and 81670765) supported collaboration between Youan Hospital, Beijing, China and the Research Unit Hypertension and Cardiovascular Epidemiology, Leuven, Belgium. Bram Janssen is a postdoctoral fellow supported by the Research Foundation Flanders (Grant Number: 12W3218).

Competing interests

The authors declare no competing interests.

Additional information

Supplementary Information The online version contains supplementary material available at <https://doi.org/10.1038/s41598-021-94136-1>.

Correspondence and requests for materials should be addressed to Y.-M.F. or J.A.S.

Reprints and permissions information is available at www.nature.com/reprints.

Publisher's note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit <http://creativecommons.org/licenses/by/4.0/>.

© The Author(s) 2021

SUPPLEMENTARY MATERIAL

This web appendix formed part of the original submission and has been peer reviewed.

Supplement to: ***Renal function in relation to fine airborne particulate matter in a representative population sample***

Ying-Mei Feng, Lutgarde Thijs, Zhen-Yu Zhang, Esmée M. Bijlens, Wen-Yi Yang, Fang-Fei Wei, Bram G. Janssen, Tim S Nawrot, Jan A. Staessen

Table of contents

Table S1	Correlation matrix of baseline covariables in men	p2
Table S2	Correlation matrix of baseline covariables in women	p3
Table S3	Baseline characteristics of participants by sex	p4
Table S4	Baseline characteristics of participants by age	p5
Table S5	Baseline characteristics of participants by smoking status	p6
Table S6	Baseline characteristics of participants by daily alcohol intake	p7
Table S7	Multivariable-adjusted cross-sectional associations of renal function with black carbon in various subgroups	p8
Table S8	Multivariable-adjusted cross-sectional associations of renal function with PM _{2.5} in various subgroups	p9
Table S9	Multivariable-adjusted between changes from baseline to follow-up in renal function and in the black carbon exposure in various subgroups	p10
Table S10	Multivariable-adjusted between changes from baseline to follow-up in renal function and in the PM _{2.5} exposure in various subgroups	p11
Table S11	Cross-sectional associations of renal function with black carbon and PM _{2.5} with a reduced set of covariables	p12
Table S12	Longitudinal associations of renal function with black carbon and PM _{2.5} with a reduced set of covariables	p13
Figure S1	Distribution plots serum creatinine and eGFR by sex and age	p14
Figure S2	Association of serum creatinine and eGFR with age by sex	p15

Supplementary Table 1. Correlation coefficients between continuously distributed baseline covariables in 404 men.

	SCRT	eGFR	Age	SBP	DBP	MAP	HR	BMI	GLC	TC	HC	THCR	LGGT	LTCAL	SOC
SCRT	—														
eGFR	-0.75§	—													
Age	0.20§	-0.72§	—												
SBP	0.17‡	-0.37§	0.43§	—											
DBP	0.08	-0.18‡	0.13*	0.49§	—										
MAP	0.13†	-0.30§	0.30§	0.83§	0.89	—									
HR	-0.05	0.04	-0.01	0.13†	0.23	0.22§	—								
BMI	0.16†	0.31§	0.31§	0.21§	0.31	0.31§	0.07	—							
GLC	0.04	-0.17‡	0.20§	0.24§	-0.01	0.12*	0.07	0.18‡	—						
TC	0.02	-0.14†	0.18‡	0.16†	0.28	0.27§	0.13†	0.20§	0.004	—					
HC	-0.15†	0.15†	-0.09	-0.003	0.07	0.04	0.04	-0.22§	-0.10*	0.27§	—				
THCR	0.15†	-0.24§	0.23§	0.12*	0.12	0.14†	0.08	0.35§	0.11*	0.49§	-0.68§	—			
LGGT	0.12*	-0.13	0.09	0.17‡	0.26	0.26§	0.17‡	0.32§	0.07	0.30§	-0.06	0.27§	—		
LTCAL	-0.01	0.02	-0.01	-0.01	0.10	0.06	0.07	0.14†	0.04	0.01	0.03	-0.02	-0.02	—	
SOC	-0.06	0.10*	-0.21§	-0.13†	0.10*	-0.004	-0.08	-0.08	-0.11*	0.06	0.12*	-0.08	-0.03	-0.24§	—

Abbreviation: SCRT, serum creatinine concentration; eGFR, glomerular filtration rate estimated from serum creatinine; SBP, systolic blood pressure; DBP, diastolic blood pressure; MAP, mean arterial pressure; HR, heart rate; BMI, body mass index; GLC, plasma glucose; TC, total serum cholesterol; HC, high-density lipoprotein serum cholesterol; THCR, total-to-high-density lipoprotein serum cholesterol; LGGT, serum γ -glutamyltransferase; LTCAL, total daily energy expenditure in physical activity (logarithmically transformed); SEC, socioeconomic class. * $P \leq 0.05$; † $P \leq 0.01$; ‡ $P \leq 0.001$; § $P \leq 0.0001$.

Supplementary Table 2. Correlation coefficients between continuously distributed baseline covariables in 416 women.

	SCRT	eGFR	Age	SBP	DBP	MAP	HR	BMI	GLC	TC	HC	THCR	LGGT	LTCAL	SOC
SCRT	—														
eGFR	-0.76§	—													
Age	0.18‡	-0.69§	—												
SBP	0.21§	-0.46§	0.60§	—											
DBP	0.11§	-0.23§	0.23§	0.54§	—										
MAP	0.19§	-0.40§	0.48§	0.88§	0.87§	—									
HR	0.02	0.07	-0.14†	-0.02	0.20§	0.10*	—								
BMI	0.15†	-0.21§	0.21§	0.32§	0.31§	0.36§	0.17‡	—							
GLC	0.13†	-0.30§	0.37§	0.25§	0.12*	0.22§	0.05	0.17‡	—						
TC	0.12*	-0.26§	0.30§	0.27§	0.17§	0.25§	-0.004	0.16†	0.09	—					
HC	-0.09	0.10	-0.04	-0.03	-0.06	-0.05	-0.06	-0.28§	-0.15†	0.27§	—				
THCR	0.18‡	-0.28§	0.25§	0.23§	0.19§	0.24§	0.07	0.37§	0.21§	0.51§	-0.66§	—			
LGGT	0.04	-0.20§	0.29§	0.27§	0.18§	0.26§	0.09	0.18‡	0.29§	0.16§	-0.09	0.22§	—		
LTCAL	0.02	-0.16†	0.29§	0.21§	0.10§	0.18‡	-0.05	0.15†	0.09	0.09	0.09	0.06	0.11*	—	
SOC	-0.002	0.07	-0.17‡	-0.16†	0.01	-0.09	-0.03	-0.15†	-0.08	-0.05	-0.05	-0.12*	-0.09	-0.25*	—

Abbreviation: SCRT, serum creatinine concentration; eGFR, glomerular filtration rate estimated from serum creatinine; SBP, systolic blood pressure; DBP, diastolic blood pressure; MAP, mean arterial pressure; HR, heart rate; BMI, body mass index; GLC, plasma glucose; TC, total serum cholesterol; HC, high-density lipoprotein serum cholesterol; THCR, total-to-high-density lipoprotein serum cholesterol; LGGT, serum γ -glutamyltransferase; LTCAL, total daily energy expenditure in physical activity (logarithmically transformed); SEC, socioeconomic class. * $P \leq 0.05$; † $P \leq 0.01$; ‡ $P \leq 0.001$; § $P \leq 0.0001$.

Supplementary Table 3. Baseline characteristics of participants by sex.

Characteristic	Men	Women	P
All in category (n)	404	416	
Smokers (n [%])	85 (21.0)	83 (20.0)	0.70
Alcohol intake ≥ 5 g/day (n [%])			
Hypertension (n [%])	179 (44.3)	162 (38.9)	0.12
Antihypertensive treatment (n [%])	101 (25.0)	110 (26.4)	0.64
Statin treatment (n [%])	50 (12.4)	56 (13.5)	0.64
Diabetes mellitus (n [%])	18 (4.5)	14 (3.4)	0.42
Microalbuminuria (n [%])	308 (80.6)	315 (79.2)	0.61
CKD, stage ≥ 3 (n [%])	25 (6.2)	44 (10.6)	0.0006
Mean of characteristic			
Age (years)	50.7 (16.1)	51.6 (15.2)	0.40
Body mass index (kg/m ²)	26.7 (3.9)	26.3 (4.7)	0.15
Systolic pressure (mm Hg)	131.0 (15.4)	127.8 (19.2)	0.008
Diastolic pressure (mm Hg)	81.6 (9.6)	77.8 (9.1)	<0.0001
Mean arterial pressure (mm Hg)	98.1 (10.0)	94.5 (10.9)	<0.0001
Heart rate (beats per minute)	62.1 (9.7)	64.8 (9.6)	<0.0001
Biochemical data			
Serum creatinine (μ mol/L)	94.2 (15.3)	86.2 (13.5)	<0.0001
eGFR (mL/min/1.73 m ²)	83.8 (16.6)	78.1 (15.7)	<0.0001
Total cholesterol (mmol/L)	5.12 (0.94)	5.39 (0.98)	<0.0001
HDL cholesterol (mmol/L)	1.27 (0.28)	1.57 (0.34)	<0.0001
Total-to-HDL cholesterol ratio	4.19 (1.06)	3.55 (0.90)	<0.0001
Plasma glucose (mmol/L)	5.05 (0.96)	4.84 (0.61)	0.0002
γ -glutamyltransferase (U/L)	35 (13–89)	24 (9–64)	<0.0001
Airborne particulate			
Black carbon (μ g/m ³)	1.17 (0.20)	1.17 (0.20)	0.69
PM _{2.5} (μ g/m ³)	13.5 (0.92)	13.5 (0.91)	0.57

Abbreviations: CKD, chronic kidney disease; eGFR, glomerular filtration rate estimated from serum creatinine by the CKD-EPI formula; HDL, high-density lipoprotein. Blood pressure was the average of five consecutive auscultatory readings. Hypertension was a blood pressure of ≥ 140 mm Hg systolic or ≥ 90 mm Hg diastolic, or use of antihypertensive drugs. Diabetes mellitus was a fasting plasma glucose >7.0 mmol/L (>126 mg/dL) or use of antidiabetic agents. The assessment of microalbuminuria ($>3.5/>2.5$ mg per mmol creatinine in women/men) was available in 780 participants. The central tendency (data spread) is given as arithmetic mean (SD) or median (5th–95th percentile interval). P-values indicate the significance of the sex differences.

Supplementary Table 4. Baseline characteristics of participants by age.

Characteristic	<60 years	≥60years	P
All in category (n)	588	232	
Women (n [%])	297 (50.5)	119 (51.3)	0.84
Alcohol intake ≥5g/day (n [%])	265 (45.1)	67 (28.9)	<0.0001
Hypertension (n [%])	177 (30.1)	164 (70.7)	<0.0001
Antihypertensive treatment (n [%])	97 (16.5)	114 (49.1)	<0.0001
Statin treatment (n [%])	48 (8.2)	58 (25.0)	<0.0001
Diabetes mellitus (n [%])	12 (2.0)	20 (8.6)	<0.0001
Microalbuminuria (n [%])	14 (2.5)	15 (6.9)	0.004
CKD, stage ≥3 (n [%])	11 (1.9)	68 (29.3)	<0.0001
Mean of characteristic			
Age (years)	43.7 (11.5)	69.9 (6.3)	0.04
Body mass index (kg/m ²)	26.1 (4.4)	27.6 (4.1)	<0.0001
Systolic pressure (mm Hg)	124.4 (13.7)	142.1 (19.4)	0.004
Diastolic pressure (mm Hg)	80.0 (9.7)	79.0 (9.0)	0.002
Mean arterial pressure (mm Hg)	94.8 (10.3)	100.0 (10.6)	0.0005
Heart rate (beats per minute)	64.1 (9.5)	61.9 (10.0)	0.53
Biochemical data			
Serum creatinine (μmol/L)	84.8 (12.4)	90.6 (20.9)	0.0001
eGFR (mL/min/1.73 m ²)	86.3 (14.4)	67.1 (12.7)	<0.0001
Total cholesterol (mmol/L)	5.21 (0.97)	5.38 (0.94)	0.02
HDL cholesterol (mmol/L)	1.43 (0.35)	1.40 (0.35)	0.18
Total-to-HDL cholesterol ratio	3.80 (1.02)	4.03 (1.06)	0.003
Plasma glucose (mmol/L)	4.84 (0.61)	5.21 (1.13)	<0.0001
γ-glutamyltransferase (U/L)	29 (10–71)	32 (12–67)	0.36
Airborne particulate			
Black carbon (μg/m ³)	1.19 (0.20)	1.13 (0.17)	<0.0001
PM _{2.5} (μg/m ³)	13.6 (0.95)	13.3 (0.79)	<0.0001

Abbreviations: CKD, chronic kidney disease; eGFR, glomerular filtration rate estimated from serum creatinine by the CKD-EPI formula; HDL, high-density lipoprotein. Blood pressure was the average of five consecutive auscultatory readings. Hypertension was a blood pressure of ≥140 mm Hg systolic or ≥90 mm Hg diastolic, or use of antihypertensive drugs. Diabetes mellitus was a fasting plasma glucose of >7.0 mmol/L (>126 mg/dL) or use of antidiabetic agents. The assessment of microalbuminuria (>3.5/>2.5 mg per mmol creatinine in women/men) was available in 780 participants. The central tendency (data spread) is given as arithmetic mean (SD) or median (5th–5th percentile interval). P-values indicate the significance of the differences between younger and older participants.

Supplementary Table 5. Baseline characteristics of participants by smoking status.

Characteristic	Non-smokers	Smokers	P
All in category (n)	652	168	
Women (n [%])	333 (51.1)	83 (49.4)	0.70
Alcohol intake ≥ 5 g/day (n [%])			
Hypertension (n [%])	292 (44.8)	49 (29.2)	0.002
Antihypertensive treatment (n [%])	181 (27.8)	30 (17.9)	0.009
Statin treatment (n [%])	93 (14.3)	13 (7.7)	0.02
Diabetes mellitus (n [%])	28 (4.3)	4 (2.4)	0.25
Microalbuminuria (n [%])	507 (81.1)	116 (74.8)	0.08
CKD, stage ≥ 3 (n [%])	60 (6.2)	9 (10.6)	0.12
Mean of characteristic			
Age (years)	51.7 (15.9)	48.9 (14.3)	0.04
Body mass index (kg/m ²)	26.8 (4.4)	25.3 (4.0)	<0.0001
Systolic pressure (mm Hg)	130.3 (17.8)	125.9 (15.7)	0.004
Diastolic pressure (mm Hg)	80.2 (9.6)	77.6 (8.8)	0.002
Mean arterial pressure (mm Hg)	96.9 (10.7)	93.7 (9.7)	0.0005
Heart rate (beats per minute)	63.4 (9.8)	63.9 (9.5)	0.53
Biochemical data			
Serum creatinine (μ mol/L)	87.2 (16.3)	83.6 (11.5)	0.007
eGFR (mL/min/1.73 m ²)	79.9 (16.5)	84.9 (15.5)	0.0004
Total cholesterol (mmol/L)	5.25 (0.97)	5.25 (0.95)	0.96
HDL cholesterol (mmol/L)	1.43 (0.35)	1.41 (0.35)	0.52
Total-to-HDL cholesterol ratio	3.85 (1.02)	3.91 (1.09)	0.49
Plasma glucose (mmol/L)	4.96 (0.86)	4.86 (0.55)	0.13
γ -glutamyltransferase (U/L)	29 (10–66)	32 (11–76)	0.33
Airborne particulate			
Black carbon (μ g/m ³)	1.16 (0.19)	1.21 (0.21)	0.004
PM _{2.5} (μ g/m ³)	13.4 (0.90)	13.6 (0.96)	0.02

Abbreviations: CKD, chronic kidney disease; eGFR, glomerular filtration rate estimated from serum creatinine by the CKD-EPI formula; HDL, high-density lipoprotein. Blood pressure was the average of five consecutive auscultatory readings. Hypertension was a blood pressure of ≥ 140 mm Hg systolic or ≥ 90 mm Hg diastolic, or use of antihypertensive drugs. Diabetes mellitus was a fasting plasma glucose of >7.0 mmol/L (>126 mg/dL) or use of antidiabetic agents. The assessment of microalbuminuria ($>3.5/>2.5$ mg per mmol creatinine in women/men) was available in 780 participants. The central tendency (data spread) is given as arithmetic mean (SD) or median (5th–5th percentile interval). P-values indicate the significance of the differences between non-smokers and smokers.

Supplementary Table 6. Baseline characteristics of participants by daily alcohol intake.

Characteristic	<5g/day	≥5 g/day	P
All in category (n)	488	332	
Women (n [%])	325 (66.6)	91 (27.4)	<0.0001
Smokers (n [%])	88 (18.0)	80 (24.1)	0.03
Hypertension (n [%])	210 (43.0)	131 (39.5)	0.31
Antihypertensive treatment (n [%])	135 (27.7)	76 (22.9)	0.12
Statin treatment (n [%])	69 (14.1)	37 (11.1)	0.21
Diabetes mellitus (n [%])	27 (5.5)	5 (1.5)	0.004
Microalbuminuria (n [%])	360 (77.1)	263 (84.0)	0.02
CKD, stage ≥3 (n [%])	57 (6.2)	12 (10.6)	<0.0001
Mean of characteristic			
Age (years)	53.2 (15.8)	48.2 (14.9)	0.04
Body mass index (kg/m ²)	26.7 (4.6)	26.2 (4.0)	<0.0001
Systolic pressure (mm Hg)	129.7 (18.2)	129.0 (16.4)	0.004
Diastolic pressure (mm Hg)	79.0 (9.3)	80.7 (9.7)	0.002
Mean arterial pressure (mm Hg)	95.9 (10.6)	96.8 (10.7)	0.0005
Heart rate (beats per minute)	64.0 (9.6)	62.7 (9.8)	0.53
Biochemical data			
Serum creatinine (μmol/L)	84.7 (16.9)	88.9 (12.8)	<0.0001
eGFR (mL/min/1.73 m ²)	78.5 (16.2)	84.5 (16.1)	<0.0001
Total cholesterol (mmol/L)	5.29 (0.97)	5.19 (0.96)	0.15
HDL cholesterol (mmol/L)	1.45 (0.36)	1.39 (0.33)	0.01
Total-to-HDL cholesterol ratio	3.83 (1.01)	3.92 (1.06)	0.21
Plasma glucose (mmol/L)	4.97 (0.92)	4.90 (0.61)	0.21
γ-glutamyltransferase (U/L)	27 (10–64)	33 (11–81)	0.009
Airborne particulate			
Black carbon (μg/m ³)	1.17 (0.20)	1.16 (0.19)	0.61
PM _{2.5} (μg/m ³)	13.5 (0.92)	13.5 (0.91)	0.87

Abbreviations: CKD, chronic kidney disease; eGFR, glomerular filtration rate estimated from serum creatinine by the CKD-EPI formula; HDL, high-density lipoprotein. Blood pressure was the average of five consecutive auscultatory readings. Hypertension was a blood pressure of ≥140 mm Hg systolic or ≥90 mm Hg diastolic, or use of antihypertensive drugs. Diabetes mellitus was a fasting plasma glucose of >7.0 mmol/L (>126 mg/dL) or use of antidiabetic agents. The assessment of microalbuminuria (>3.5/>2.5 mg per mmol creatinine in women/men) was available in 780 participants. The central tendency (data spread) is given as arithmetic mean (SD) or median (5th–5th percentile interval). P-values indicate the significance of the differences between participants dichotomised by a daily alcohol of 5 g per day.

Supplementary Table 7. Multivariable-adjusted cross-sectional associations of renal function with black carbon in various subgroups.

Group analysed Renal function trait	Estimate (95% CI)	P	Estimate (95% CI)	P	Pint
Sex	Women (N = 416)		Men (N = 404)		
Serum creatinine ($\mu\text{mol/L}$)	0.17 (-1.00, 1.34)	0.77	0.11 (-1.38, 1.60)	0.89	0.45
eGFR (mL/min/1.73 m^2)	0.04 (-1.11, 1.19)	0.94	0.15 (-1.03, 1.34)	0.80	0.79
Prevalence					
Chronic kidney disease (OR)	-0.12 (-0.58, 0.33)	0.60	-0.25 (-0.80, 0.31)	0.38	0.76
Microalbuminuria (OR)	-0.02 (-0.27, 0.24)	0.72	0.12 (-0.17, 0.40)	0.42	0.87
Age	<60 years (N = 588)		≥ 60 years (N = 232)		
Serum creatinine ($\mu\text{mol/L}$)	0.32 (-0.60, 1.23)	0.50	0.27 (-2.21, 2.74)	0.83	0.70
eGFR (mL/min/1.73 m^2)	-0.03 (-1.03, 0.97)	0.96	-0.22 (-1.81, 1.38)	0.79	0.48
Prevalence					
Chronic kidney disease (OR)	-0.039 (...)	...	-0.16 (-0.55, 0.24)	0.44	0.94
Microalbuminuria (OR)	-0.02 (-0.25, 0.22)	0.89	0.34 (-0.06, 0.75)	0.10	0.12
Smoking status	Non-smokers (N = 685)		Smokers (N = 135)		
Serum creatinine ($\mu\text{mol/L}$)	0.49 (-0.63, 1.61)	0.39	-0.52 (-1.93, 0.89)	0.48	0.36
eGFR (mL/min/1.73 m^2)	-0.36 (-1.36, 0.64)	0.47	0.81 (-0.82, 2.43)	0.34	0.49
Prevalence					
Chronic kidney disease (OR)	-0.06 (-0.41, 0.29)	0.73	-0.94	NA	0.71
Microalbuminuria (OR)	0.09 (-0.13, 0.31)	0.43	-0.26 (-0.57, 0.05)	0.10	0.75
Alcohol consumption	<5 g/day (N = 350)		≥ 5 g/day (N = 470)		
Serum creatinine ($\mu\text{mol/L}$)	-0.06 (-1.37, 1.25)	0.93	0.89 (-0.36, 2.14)	0.17	0.69
eGFR (mL/min/1.73 m^2)	0.18 (-0.94, 1.30)	0.57	-0.77 (-2.10, 0.56)	0.57	0.80
Prevalence					
Chronic kidney disease (OR)	-0.29 (-0.64, -0.06)	0.18	0.86 (-0.14, 1.86)	0.09	0.38
Microalbuminuria (OR)	-0.06 (-0.30, 0.18)	0.12	0.27 (-0.10, 0.64)	0.15	0.49

eGFR is the glomerular filtration rate estimated from serum creatinine by the CKD-EPI formula. Associations sizes were derived from mixed models that combined baseline and follow-up data (see Table 3). For chronic kidney disease (eGFR <60 mL/min/1.73 m²) and microalbuminuria (>3.5/>2.5 mg per mmol creatinine in women/men), association sizes are expressed as odds ratios (OR). Mixed models accounted for clustering of the baseline and follow-up data among participants living at the same address and were adjusted for sex, age (linear and squared term), mean arterial pressure, heart rate, body mass index, plasma glucose, total-to-HDL cholesterol ratio, γ -glutamyltransferase, smoking, physical activity, socioeconomic class, and antihypertensive treatment (by drug class). An ellipsis indicates that the model did not converge. Association sizes, given with 95% confidence interval, were expressed for an interquartile range increment in the airborne particulate. Pint denotes the between-group significance of the difference in the association sizes.

Supplementary Table 8. Multivariable-adjusted cross-sectional associations of renal function with PM_{2.5} in various subgroups.

Group analysed Renal function trait	Estimate (95% CI)	P	Estimate (95% CI)	P	Pint
Sex	Women (N = 416)		Men (N = 404)		
Serum creatinine (μmol/L)	0.06 (-1.14, 1.26)	0.92	-0.03 (-1.48, 1.42)	0.97	0.56
eGFR (mL/min/1.73 m ²)	0.05 (-1.13, 1.23)	0.93	0.28 (-0.88, 1.44)	0.64	0.78
Prevalence					
Chronic kidney disease (OR)	-0.13 (-0.58, 0.32)	0.56	-0.23 (-0.76, 0.30)	0.40	0.79
Microalbuminuria (OR)	-0.07 (-0.32, 0.18)	0.60	0.13 (-0.16, 0.42)	0.39	0.83
Age	<60 years (N = 588)		≥60 years (N = 232)		
Serum creatinine (μmol/L)	0.18 (-0.76, 0.76)	0.71	0.25 (-2.13, 2.63)	0.84	0.67
eGFR (mL/min/1.73 m ²)	0.02 (-1.00, 1.00)	0.97	0.03 (-1.50, 1.56)	0.97	0.63
Prevalence					
Chronic kidney disease (OR)	-0.0004 (...)	...	-0.16 (-0.53, 0.21)	0.41	0.85
Microalbuminuria (OR)	-0.06 (-0.31, 0.18)	0.61	0.27 (-0.16, 0.70)	0.23	0.19
Smoking status	Non-smokers (N = 685)		Smokers (N = 135)		
Serum creatinine (μmol/L)	0.38 (-0.76, 1.51)	0.52	-0.51 (-1.92, 0.90)	0.49	0.47
eGFR (mL/min/1.73 m ²)	-0.27 (-1.27, 0.73)	0.59	0.76 (-0.85, 2.37)	0.37	0.60
Prevalence					
Chronic kidney disease (OR)	-0.12 (-0.45, 0.21)	0.47	-0.23	NA	0.57
Microalbuminuria (OR)	0.10 (-0.14, 0.34)	0.39	-0.31 (-0.60, -0.02)	0.04	0.51
Alcohol consumption	<5 g/day (N = 350)		≥5 g/day (N = 470)		
Serum creatinine (μmol/L)	-0.03 (-1.36, 1.30)	0.97	0.54 (-0.68, 1.76)	0.38	0.77
eGFR (mL/min/1.73 m ²)	0.09 (-1.05, 1.23)	0.88	-0.45 (-1.74, 0.84)	0.49	0.81
Prevalence					
Chronic kidney disease (OR)	-0.30 (-0.65, 0.05)	0.09	0.64 (-0.24, 1.52)	0.15	0.35
Microalbuminuria (OR)	-0.08 (-0.31, 0.15)	0.49	0.23 (-0.14, 0.60)	0.23	0.33

eGFR is the glomerular filtration rate estimated from serum creatinine by the CKD-EPI formula. Associations sizes were derived from mixed models that combined baseline and follow-up data (see Table 3). For chronic kidney disease (eGFR < 60 mL/min/1.73 m²) and microalbuminuria (>3.5/>2.5 mg per mmol creatinine in women/men), association sizes are expressed as odds ratios (OR). Mixed models accounted for clustering of the baseline and follow-up data among participants living at the same address and were adjusted for sex, age (linear and squared term), mean arterial pressure, heart rate, body mass index, plasma glucose, total-to-HDL cholesterol ratio, γ-glutamyltransferase, smoking, physical activity, socioeconomic class, and antihypertensive treatment (by drug class). Association sizes, given with 95% confidence interval, were expressed for an interquartile range increment in the airborne particulate. An ellipsis indicates that the model did not converge. Pint denotes the between-group significance of the difference in the association sizes.

Supplementary Table 9. Multivariable-adjusted associations between changes from baseline to follow-up in renal function and in the black carbon exposure.

Group analysed Renal function trait	N	Estimate (95% CI)	P	N	Estimate (95% CI)	P	Pint
Sex		Women (N = 328)			Men (N = 325)		
Serum creatinine (%)	328	0.38 (-0.85, 1.60)	0.52	325	-0.12 (-2.18, 1.93)	0.90	0.43
eGFR (%)	328	-0.42 (-2.18, 1.33)	0.62	325	-0.10 (-1.67, 1.46)	0.89	0.58
Incidence CKD (OR)	24/293	0.72 (0.17, 1.28)	0.01	24/307	0.30 (-0.34, 0.94)	0.36	0.04
Age		<60 years (N = 481)					
Serum creatinine (%)	481	0.15 (-1.40, 1.69)	0.85	172	-0.56 (-2.71, 1.59)	0.60	0.24
eGFR (%)	481	-0.53 (-1.80, 0.74)	0.41	172	0.73 (-1.75, 3.21)	0.55	0.20
Incidence CKD (OR)	8/470	0.07 (-0.59, 0.73)	0.83	40/130	0.46 (-0.08, 1.01)	0.09	0.69
Smoking status		Non-smokers (N = 529)					
Serum creatinine (%)	529	-0.10 (-1.03, 0.82)	0.83	124	0.17 (-33.57, 33.92)	0.96	0.24
eGFR (%)	529	0.16 (-1.04, 1.36)	0.79	124	-2.00 (-22.1, 18.14)	0.43	0.17
Incidence CKD (OR)	41/482	0.31 (-0.14, 0.77)	0.18	7/118	132.90	NA	0.16
Alcohol consumption		<5 g/day (N = 380)					
Serum creatinine (%)	380	0.22 (-0.89, 1.34)	0.69	273	-0.11 (-2.47, 2.26)	0.93	0.89
eGFR (%)	380	-0.32 (-1.77, 1.14)	0.67	273	-0.14 (-2.04, 0.76)	0.88	0.79
Incidence CKD (OR)	37/309	0.41 (-0.06, 0.87)	0.08	11/291	-0.12	NA	0.04

eGFR is the glomerular filtration rate estimated from serum creatinine by the CKD-EPI formula. For continuously distributed variables (serum creatinine and eGFR), changes were computed as the follow-up minus baseline values and expressed as a percentage of the baseline value. Incidence refers to new-onset chronic kidney disease (<60 mL/min/1.73 m²). N indicates the number of participants in the analysis or the number of new-onset cases/number of participants at risk. Associations accounted for clustering of data among participants living at the same address and were adjusted for sex, baseline age (linear and square term), socio-economic class, follow-up duration, baseline body mass index, the baseline value of and change during follow-up in mean arterial pressure, heart rate, plasma glucose, the total-to-HDL cholesterol ratio, γ-glutamyltransferase, calories spent in physical activity, smoking status, and the intake of antihypertensive drugs (all drugs combined). Association sizes were expressed for an interquartile range increment in the airborne particulate. Pint denotes the between-group significance of the difference in the association sizes.

Supplementary Table 10. Multivariable-adjusted associations between changes from baseline to follow-up in renal function and in PM_{2.5} exposure.

Group analysed Renal function trait	N	Estimate (95% CI)	P	N	Estimate (95% CI)	P	Pint
Sex		Women (N = 416)			Men (N = 404)		
Serum creatinine (%)	328	0.45 (-0.81, 1.71)	0.46	325	-0.02 (-2.04, 1.99)	0.98	0.72
eGFR (%)	328	-0.51 (-2.32, 1.29)	0.55	325	-0.02 (-1.55, 1.50)	0.98	0.43
Incidence CKD (OR)	24/293	0.56 (-0.07, 1.20)	0.08	24/307	0.10 (-0.45, 0.65)	0.72	0.17
Age		<60 years (N = 481)			≥ 60 years (N = 172)		
Serum creatinine (%)	481	0.20 (-1.37, 1.77)	0.80	172	-0.17 (-2.26, 1.93)	0.87	0.30
eGFR (%)	481	-0.56 (-1.85, 0.73)	0.39	172	0.30 (-2.12, 2.71)	0.80	0.19
Incidence CKD (OR)	8/470	-0.18 (-1.01, 0.66)	0.67	40/130	0.27 (-0.25, 0.79)	0.31	0.50
Smoking status		Non-smokers (N = 529)			Smokers (N = 124)		
Serum creatinine (%)	529	-0.10 (-1.03, 0.83)	0.82	124	0.74 (-32.98, 34.46)	0.83	0.30
eGFR (%)	529	0.23 (-0.97, 1.43)	0.71	124	-2.56 (-22.45, 17.33)	0.35	0.19
Incidence CKD (OR)	41/482	0.14 (-0.31, 0.60)	0.53	7/118	126.68	NA	0.54
Alcohol consumption		<5 g/day (N = 380)			≥5 g/day (N = 273)		
Serum creatinine (%)	380	0.38 (-0.76, 1.52)	0.51	273	-0.09 (-2.39, 2.22)	0.94	0.91
eGFR (%)	380	-0.60 (-2.08, 0.88)	0.42	273	0.09 (-1.76, 1.94)	0.92	0.56
Incidence CKD (OR)	37/309	0.23 (-0.27, 0.72)	0.36	11/291	-0.26	NA	0.16

eGFR is the glomerular filtration rate estimated from serum creatinine by the CKD-EPI formula. For continuously distributed variables (serum creatinine and eGFR), changes were computed as the follow-up minus baseline values and expressed as a percentage of the baseline value. Incidence refers to new-onset chronic kidney disease (<60 mL/min/1.73 m²). N indicates the number of participants in the analysis or the number of new-onset cases/number of participants at risk. Associations accounted for clustering of data among participants living at the same address and were adjusted for sex, baseline age (linear and square term), socio-economic class, follow-up duration, baseline body mass index, the baseline value of and change during follow-up in mean arterial pressure, heart rate, plasma glucose, the total-to-HDL cholesterol ratio, γ-glutamyltransferase, calories spent in physical activity, smoking status, and the intake of antihypertensive drugs (all drugs combined). Association sizes were expressed for an interquartile range increment in the airborne particulate. Pint denotes the between-group significance of the difference in the association sizes.

Supplementary Table 11. Multivariable-adjusted cross-sectional associations of renal function with black carbon and PM_{2.5} with reduced adjustment.

Airborne particulate Renal function	Baseline only (n=820)		Follow-up only (n=653)		Baseline and follow-up (n=820)	
	Estimate (95% CI)	P	Estimate (95% CI)	P	Estimate (95% CI)	P
Black carbon						
Serum creatinine (μmol/L)	0.18 (-0.77 to 1.14)	0.70	0.07 (-1.50 to 1.64)	0.93	0.21 (-0.89 to 1.31)	0.71
eGFR (mL/min/1.73 m ²)	0.03 (-0.83 to 0.89)	0.95	-0.17 (-1.27 to 0.93)	0.77	-0.01 (-0.86 to 0.85)	0.98
Prevalence						
eGFR <60 mL/min/1.73 m ² (%)	-0.03 (-0.34 to 0.28)	0.85	0.09 (-0.24 to 0.42)	0.60	0.05 (-0.22 to 0.32)	0.73
Microalbuminuria (%)	0.04 (-0.16, 0.24)	0.70	-0.00 (-0.20, 0.19)	0.98	0.01 (-0.13, 0.15)	0.91
PM _{2.5}						
Serum creatinine (μmol/L)	0.14 (-0.82 to 1.10)	0.78	-0.07 (-1.64 to 1.50)	0.93	0.12 (-1.00, 1.24)	0.84
eGFR (mL/min/1.73 m ²)	0.04 (-0.84 to 0.94)	0.92	-0.12 (-1.22 to 0.98)	0.83	0.01 (-0.85 to 0.87)	0.98
Prevalence						
eGFR <60 mL/min/1.73 m ² (%)	-0.01 (-0.30 to 0.28)	0.96	-0.00 (-0.32 to 0.31)	0.99	0.01 (-0.26 to 0.28)	0.96
Microalbuminuria (%)	0.01 (-0.17, 0.19)	0.89	-0.01 (-0.19, 0.17)	0.90	-0.01 (-0.15, 0.13)	0.91

eGFR is the glomerular filtration rate estimated from serum creatinine by the CKD-EPI formula. Associations sizes were derived from mixed models, which accounted for clustering of the baseline and follow-up data among participants living at the same address and were adjusted for sex, age (linear and squared term) and antihypertensive treatment (all drug classes combined). Association sizes, given with 95% confidence interval, were expressed for an interquartile range increment in the airborne particulate.

Supplementary Table 12. Multivariable-adjusted longitudinal associations of renal function with black carbon and PM_{2.5} with reduced adjustment.

Group analysed Renal function trait	N	Black carbon		PM _{2.5}	
		Estimate (95% CI)	P	Estimate (95% CI)	P
Serum creatinine (%)	653	-0.07 (-1.68, 1.54)	0.93	-0.15 (-1.76, 1.46)	0.86
eGFR (%)	653	-0.05 (-1.17, 1.07)	0.97	-0.02 (-1.14, 1.10)	0.96
Incidence of CKD (odds ratio)	48/600	0.21 (-0.16, 0.59)	0.27	0.07 (-0.29, 0.44)	0.69

eGFR is the glomerular filtration rate estimated from serum creatinine by the CKD-EPI formula. For continuously distributed variables (serum creatinine and eGFR), changes were computed as the follow-up minus baseline values and expressed as a percentage of the baseline value. Incidence refers to new-onset chronic kidney disease (<60 mL/min/1.73 m²). N indicates the number of participants in the analysis or the number of new-onset cases/number of participants at risk. The change in the exposure to airborne particulate was expressed as the logarithmically transformed (log₁₀) ratio of the follow-up-to-the-baseline value. Associations accounted for clustering of data among participants living at the same address and were adjusted for sex, baseline age (linear and square term), follow-up duration and the intake of antihypertensive drugs (all drug classes combined). Association sizes were expressed for an interquartile range increment in the airborne particulate.

Supplementary Figure S1.

Distributions of serum creatinine (A, C) and the glomerular filtration rate estimated from serum creatinine (B, D) in 404 men (A, B) and in 416 women (C, D). The red and blue dotted lines represent the normal and kernel density distributions. The P values are for departure of the actually observed distribution from normality according to the Shapiro-Wilk statistic. Skewness and kurtosis were computed as the third and fourth moments about the mean divided by the cube of the standard deviation.

Supplementary Figure S2.

Association of serum creatinine (A, B) and the glomerular filtration rate estimated from serum creatinine (C, D) in 404 men and 416 women by fourths of the age distribution.